Publications 318
#1Carlos Stecca (Princess Margaret Cancer Centre)H-Index: 4
#2Osama Abdeljalil (Princess Margaret Cancer Centre)H-Index: 1
Last. Srikala S. Sridhar (U of T: University of Toronto)H-Index: 31
view all 3 authors...
Despite significant progress, metastatic urothelial cancer remains an incurable condition with a limited life expectancy. Platinum-based chemotherapy is still the mainstay of treatment for metastatic disease, but immunotherapy, antibody drug conjugates, and targeted agents have shown encouraging results in several recent practice changing trials. In this review, we discuss the standard of care, recent therapeutic advances, ongoing clinical trials, and future perspectives in metastatic urothelial...
#1Eoghan Ruadh Malone (Princess Margaret Cancer Centre)H-Index: 3
#2Hao-Wen Sim (Princess Margaret Cancer Centre)H-Index: 12
Last. Aaron R. Hansen (Princess Margaret Cancer Centre)H-Index: 33
view all 9 authors...
Introduction null The anti-PD-1 immune checkpoint inhibitor nivolumab is currently approved for the treatment of patients with metastatic renal cell carcinoma (mRCC); approximately 25% of patients respond. We hypothesized that we could identify a biomarker of response using radiomics to train a machine learning classifier to predict nivolumab response outcomes. null Methods null Patients with mRCC of different histologies treated with nivolumab in a single institution between 2013 and 2017 were ...
#1Camilla ZimmermannH-Index: 62
#2Ashley PopeH-Index: 10
Last. Srikala S. Sridhar (Princess Margaret Cancer Centre)H-Index: 31
view all 25 authors...
BACKGROUND Routine early palliative care (EPC) improves quality of life (QoL) for patients with advanced cancer, but it may not be necessary for all patients. We assessed the feasibility of Symptom screening with Targeted Early Palliative care (STEP) in a phase II trial. METHODS Patients with advanced cancer were recruited from medical oncology clinics. Symptoms were screened at each visit using the Edmonton Symptom Assessment System-revised (ESAS-r); moderate to severe scores (screen-positive) ...
#1Srikala S. SridharH-Index: 31
#2Thomas PowlesH-Index: 92
Last. Bo HuangH-Index: 107
view all 15 authors...
#1Thomas PowlesH-Index: 92
#2Daniel P. PetrylakH-Index: 52
Last. Jeanny B. Aragon-ChingH-Index: 25
view all 16 authors...
INTRODUCTION AND OBJECTIVE:In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance+best supportive care (BSC) significantly prolonged overall survival (OS) vs BSC alone in pa...
#1David D'Andrea (Medical University of Vienna)H-Index: 18
#2Peter C. Black (UBC: University of British Columbia)H-Index: 53
Last. Srikala S. SridharH-Index: 31
view all 26 authors...
Purpose:We investigated the pathological response rates and survival associated with 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) in patients with cT2-4N0M0 muscle invasive bladd...
#1David D'Andrea (Medical University of Vienna)H-Index: 18
#2Peter C. Black (UBC: University of British Columbia)H-Index: 53
Last. Laura Maria Krabbe (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
view all 40 authors...
PURPOSE To assess the association of patient age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS We analyzed data from 1105 patients with MIBC. Patients age was evaluated as continuous variable and stratified in quartiles. Pathologic objective response (pOR; ypT0-Ta-Tis-T1N0) and pathologic complete response (pCR; ypT0N0), as well survival outcomes were assessed. We used data of 395 patients from The Cancer Genome Atlas (TC...
#1Jean-Michel LavoieH-Index: 8
#2Srikala S. Sridhar (U of T: University of Toronto)H-Index: 31
Last. Bernhard J. Eigl (UBC: University of British Columbia)H-Index: 5
view all 7 authors...
Background Metastatic urothelial carcinoma (mUC) historically is treated with first-line platinum-based combination chemotherapy, preferably cisplatin plus gemcitabine whenever possible. In recent years, multiple classes of targeted therapy have demonstrated benefit, with some receiving approval in mUC. This review will summarize phase III efficacy and safety data for targeted agents, principally immune checkpoint inhibitors (ICIs), as either first-line or first-line switch-maintenance therapy f...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.